Ganzenmueller Tina, Karaguelle Deniz, Schmitt Corinna, Puppe Wolfram, Stachan-Kunstyr Rita, Bronzlik Paul, Sauerbrei Andreas, Wegner Florian, Heim Albert
Institute of Virology, Hannover Medical School, Hannover, Germany.
Antivir Ther. 2012;17(1):125-8. doi: 10.3851/IMP1924.
Herpes simplex virus type 2 (HSV-2) can cause radiculo-myelitis as a neurological manifestation. We report a case of ongoing HSV-2 DNA positivity in the cerebrospinal fluid (CSF) of at least eight weeks under antiviral therapy with acyclovir in a highly immunocompromised hemato-oncologic patient with HSV-2-associated radiculitis. Upon admission, the patient presented with pain, leg paresis, and urinary incontinence, as well as pleocytosis in the CSF. Quantitative real-time PCR of the CSF at day 3 after admission revealed HSV-2 with a concentration of 2.0×10(5) copies/ml and treatment with acyclovir intravenously and prednisolone by mouth was started. Clinical symptoms resolved almost completely after approximately 3 weeks of antiviral therapy. However, CSF samples of day 12, 19, 26, 33, 39, 48 and 54 after admission showed a slow decline of HSV-2 DNA concentrations. HSV-2 DNA was still detectable (1.6×10(4) copies/ml) at day 54 after admission. Genotypic resistance testing showed, as far as available, no mutations indicative for acyclovir resistance. Since an increasing specific antibody index for HSV was observed, we speculate that the prolonged detectability of HSV-2 DNA in the CSF might not necessarily indicate ongoing viral replication but neutralized virus. Other hypotheses and the consequences on treatment are discussed. To our knowledge this is the first report about the long-term viral load kinetics of HSV-2 in the CSF of a patient with radiculitis under antiviral therapy, highlighting the need for further studies on HSV DNA kinetics in the CSF and their significance for an appropriate antiviral treatment.
单纯疱疹病毒2型(HSV - 2)可引起神经根脊髓炎作为一种神经学表现。我们报告了一例在接受阿昔洛韦抗病毒治疗的情况下,一名患有HSV - 2相关性神经根炎的高度免疫受损血液肿瘤患者的脑脊液(CSF)中HSV - 2 DNA持续阳性至少八周的病例。入院时,患者出现疼痛、腿部麻痹和尿失禁,以及脑脊液中的细胞增多。入院后第3天脑脊液的定量实时PCR显示HSV - 2浓度为2.0×10(5)拷贝/ml,开始静脉注射阿昔洛韦和口服泼尼松龙治疗。抗病毒治疗约3周后临床症状几乎完全缓解。然而,入院后第12、19、26、33、39、48和54天的脑脊液样本显示HSV - 2 DNA浓度缓慢下降。入院后第54天仍可检测到HSV - 2 DNA(1.6×10(4)拷贝/ml)。基因耐药性检测显示,就现有情况而言,没有表明对阿昔洛韦耐药的突变。由于观察到HSV的特异性抗体指数增加,我们推测脑脊液中HSV - 2 DNA的可检测性延长不一定表明病毒正在复制,而是中和的病毒。讨论了其他假设及其对治疗的影响。据我们所知,这是关于抗病毒治疗下神经根炎患者脑脊液中HSV - 2长期病毒载量动力学的首次报告,强调了对脑脊液中HSV DNA动力学及其对抗病毒治疗适当性的意义进行进一步研究的必要性。